129 related articles for article (PubMed ID: 1989785)
1. Lymphokine-activated killer cell activity in lung cancer.
LeFever A; Funahashi A
Chest; 1991 Feb; 99(2):292-7. PubMed ID: 1989785
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous lymphokine activated killer (LAK) activity in bronchoalveolar lavage cells from patients with bronchogenic carcinoma.
Stein-Streilein J; Guffee J; Ramos M; Pitchenik AE
Reg Immunol; 1989; 2(6):370-5. PubMed ID: 2485685
[TBL] [Abstract][Full Text] [Related]
3. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
LeFever AV; Funahashi A
Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
[TBL] [Abstract][Full Text] [Related]
4. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma.
Pitchenik AE; Guffee J; Stein-Streilein J
Am Rev Respir Dis; 1987 Dec; 136(6):1327-32. PubMed ID: 3500659
[TBL] [Abstract][Full Text] [Related]
5. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
6. In vitro natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma.
Dunlap NE; Lane VG; Cloud GA; Tilden AB
Cancer; 1990 Oct; 66(7):1499-504. PubMed ID: 1698527
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
8. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
9. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.
Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K
Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lymphokine-activated killer cell function by human alveolar macrophages.
Roth MD; Golub SH
Cancer Res; 1989 Sep; 49(17):4690-5. PubMed ID: 2788029
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic cell function in bronchogenic carcinoma.
Kratikanont P; deShazo RD; Banks DE; Chapman Y
Chest; 1987 Jul; 92(1):90-4. PubMed ID: 3595254
[TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
15. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
16. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
17. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
19. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
20. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells.
Bergeron D; Ouellette MJ; Lambert RD
J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
